{"url":"https://newsforagent.com/news/2026-10-28/oncoinvent-chief-medical-officer-share-options","markdown_url":"https://newsforagent.com/news/2026-10-28/oncoinvent-chief-medical-officer-share-options.md","title":"Oncoinvent Grants New Chief Medical Officer 20,000 Share Options","headline":"Oncoinvent Grants New Chief Medical Officer Zuzana Jirakova Trnkova 20,000 Share Options at NOK 67.35","description":"Oncoinvent granted new Chief Medical Officer Zuzana Jirakova Trnkova 20,000 share options at NOK 67.35, vesting 13/48 in month 13 and 1/48 monthly after.","section":"Leadership","published_at":"2026-10-28T06:23:29+00:00","modified_at":"2026-10-28T06:23:29+00:00","author":"News Desk","key_takeaways":["Oncoinvent granted Dr Zuzana Jirakova Trnkova 20,000 share options at a strike price of NOK 67.35 each.","The options vest 13/48 in the 13th month and 1/48 monthly thereafter, and lapse seven years after grant.","Trnkova was appointed Chief Medical Officer effective November 4, 2026, to lead Phase 3 preparations for Radspherin."],"companies":[{"name":"Oncoinvent","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000ck7/oncoinvent","website":"http://www.oncoinvent.com"}],"source":{"publisher":"news.cision.com","title":"Oncoinvent ASA: Grant of share options to new Chief Medical Officer","url":"https://news.cision.com/oncoinvent-asa/r/oncoinvent-asa--grant-of-share-options-to-new-chief-medical-officer,c4416272"},"other_sources":[],"tags":["Leadership","Oncoinvent"],"body_markdown":"Oncoinvent granted its new Chief Medical Officer, Dr Zuzana Jirakova Trnkova, 20,000 share options at a strike price of NOK 67.35 each, the company said on October 28, 2026. The grant was made under Oncoinvent's long-term incentive program, [news.cision.com](https://news.cision.com/oncoinvent-asa/r/oncoinvent-asa--grant-of-share-options-to-new-chief-medical-officer,c4416272) reported.\n\n## How the Oncoinvent Option Grant Is Structured\n\nEach option gives the right to acquire one share in [Oncoinvent](https://akta.pro/company-profiles/0000ck7/oncoinvent) when exercised. The options were granted without consideration, and the strike price equals the volume weighted average share price on the last day before the grant.\n\nNo options vest during the first 12 months after the grant letter. Then 13/48 of the options vest in the 13th month, and the rest vest in equal monthly instalments of 1/48, provided the holder remains employed. Options not exercised lapse seven years after the grant date.\n\nFollowing the grant, Trnkova holds 20,000 options in the company. The board said it sees an option program as an important element in attracting and retaining employees, and considers the program terms and this allocation to be at the market for comparable peers.\n\nOncoinvent said the information is subject to disclosure requirements under Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian Securities Trading Act. Chief Executive Officer Oystein Soug is listed as the contact for further information.\n\n## Oncoinvent's Earlier Leadership and Funding Moves\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Oncoinvent appointed Dr. Ramzi Amri as Chief Financial Officer effective mid-January 2026, joining from Galapagos NV with prior McKinsey & Company experience to support the post-merger public-company finance function.\n\nThe same records show Oncoinvent closed a fully underwritten rights issue of 260,000,000 new shares raising NOK 130 million (approximately USD 12 million) in December 2025, ahead of the planned Phase 2 interim readout. In October 2025 it completed a strategic merger with BerGenBio ASA and uplisted to the Oslo Stock Exchange as Oncoinvent ASA under the ticker ONCIN, issuing 117,554,012 shares to former Oncoinvent shareholders.\n\n## Radspherin Role and Phase 3 Preparation\n\nOncoinvent appointed Dr Zuzana Jiráková Trnková as Chief Medical Officer effective November 4, 2026, to lead Phase 3 preparations for Radspherin, news.cision.com reported on October 28, 2026.\n\nOncoinvent is developing Radspherin, a receptor-independent alpha radiation therapy designed to destroy residual micrometastases in the abdominal cavity. Its initial clinical focus is ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum.\n\n## Radspherin Trial Timelines\n\nOncoinvent said interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in the second half of 2026 for safety and the first half of 2027 for early efficacy.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}